Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
暂无分享,去创建一个
T. Habermann | P. L. Bergsagel | R. Fonseca | D. Dingli | S. Ansell | A. Dispenzieri | R. Kyle | Shaji K. Kumar | S. Rajkumar | S. Russell | A. Stewart | C. Reeder | V. Roy | M. Gertz | P. Greipp | S. Markovic | J. Lust | T. Witzig | M. Lacy | P. Johnston | C. Thompson | S. Hayman | F. Buadi | S. Zeldenrust | W. Morice | G. Nowakowski | D. Inwards | J. Mikhael | J. Colgan | I. Micallef | S. Russell | L. Porrata | K. D. Short | R. Dalton | P. Johnston | A. Stewart | P. Johnston | P. Bergsagel | Ivana M. Micallef | Robert A. Kyle | Joseph R. Mikhael | Robert J. Dalton | G. Nowakowski | R. Kyle
[1] N. Schmitz,et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Richardson,et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Robert A Kyle,et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.
[4] D. Esseltine,et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Crowley,et al. International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.
[6] C. Avnstorp,et al. Plasmapheresis in hyperviscosity syndrome. , 2009, Acta medica Scandinavica.
[7] J. Carpten,et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. , 2009, Cancer research.
[8] A. Siniscalchi,et al. High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia , 2009, Bone Marrow Transplantation.
[9] M. Dimopoulos,et al. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. , 2009, Clinical lymphoma & myeloma.
[10] T. Therneau,et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. , 2009, Clinical lymphoma & myeloma.
[11] S. Treon,et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] N. Munshi,et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. , 2008, Blood.
[13] E. Kimby,et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. , 2008, Blood.
[14] S. Montoto,et al. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. , 2008, Critical reviews in oncology/hematology.
[15] J. Gribben,et al. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study , 2008, Hematology.
[16] S. Treon,et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia , 2008, Leukemia & lymphoma.
[17] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[18] M. Dimopoulos,et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Robert A Kyle,et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. , 2007, Mayo Clinic proceedings.
[20] Irene Ghobrial,et al. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. , 2006, Cancer genetics and cytogenetics.
[21] H. Goldschmidt,et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] C. Tam,et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma , 2006, Cancer.
[23] E. Kimby,et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. , 2006, Blood.
[24] T. Therneau,et al. Prognostic model for disease‐specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia , 2006, British journal of haematology.
[25] J. Tamburini,et al. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients , 2005, Leukemia.
[26] A. Rossi,et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Hansmann,et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Robert A Kyle,et al. Diagnosis and management of Waldenstrom's macroglobulinemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] T. Therneau,et al. Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance. , 2005, Clinical lymphoma.
[30] P. Gobbi,et al. Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance? , 2005, Clinical Cancer Research.
[31] R. Foà,et al. Treatment of 72 newly diagnosed Waldenström macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone , 2005, Cancer.
[32] M. Rue,et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia , 2004, Cancer.
[33] M. Rue,et al. Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) , 2004, Leukemia & lymphoma.
[34] M. Dimopoulos,et al. The International Staging System for Multiple Myeloma is Applicable in Symptomatic Waldenstrom's Macroglobulinemia , 2004, Leukemia & lymphoma.
[35] T. Therneau,et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.
[36] T. Lister,et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[37] M. Dimopoulos,et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[38] A. Pestronk,et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[39] F. Cabanillas,et al. Asymptomatic Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.
[40] O. Brawley,et al. Myeloma and race: A review of the literature , 2003, Cancer and Metastasis Reviews.
[41] G. Ahmann,et al. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. , 2002, Blood.
[42] M. Dimopoulos,et al. Treatment of Waldenström's macroglobulinemia with rituximab. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] S. Montoto,et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases , 2001, British journal of haematology.
[44] R. Porcher,et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. , 2001, Blood.
[45] J. Crowley,et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). , 2001, Blood.
[46] A. Kaplan. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[47] J. Byrd,et al. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia , 2001, Journal of immunotherapy.
[48] B. Grosbois,et al. patients with the description of a new scoring system and its validation on 253 other patients. , 2000, Blood.
[49] R. Weide,et al. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti‐CD20 monoclonal antibody rituximab , 2000, British journal of haematology.
[50] E. Coche,et al. Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma , 2000, Leukemia.
[51] R. Weide,et al. Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenström's macroglobulinaemia. , 1999, Leukemia & lymphoma.
[52] J. Zaucha,et al. Effect of a 2‐hour infusion of 2‐chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia , 1999, European journal of haematology.
[53] B. Barlogie,et al. High‐dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia , 1999, British journal of haematology.
[54] F. Laurencet,et al. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies , 1999, British Journal of Cancer.
[55] B. Coiffier,et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] R. Alexanian,et al. Waldenstrom's macroglobulinemia. , 1994, Blood.
[57] M. Dimopoulos,et al. 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] N. Weiss,et al. Incidence of Waldenström's macroglobulinemia. , 1993, Blood.
[59] B. Barlogie,et al. Fludarabine therapy in Waldenström's macroglobulinemia. , 1993, The American journal of medicine.
[60] D. H. Wright,et al. The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. , 1991, The Quarterly journal of medicine.
[61] F. Mandelli,et al. Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients , 1989, Journal of internal medicine.
[62] M. Djokic. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia , 2010 .
[63] E. Kimby,et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] R A Kyle,et al. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2009, Leukemia.
[65] E. Kimby,et al. Extended rituximab therapy in Waldenström's macroglobulinemia. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[66] P. Feugier,et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. , 2004, Blood.
[67] M. Dimopoulos,et al. Waldenström's macroglobulinemia: clinical features, complications, and management. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] B. Coiffier,et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] Lust,et al. WaldenstroÈm's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil , 2000 .
[70] D. Redfield,et al. Waldenström's macroglobulinemia: long-term results with the M-2 protocol. , 1991, Cancer investigation.